Accéder au contenu principal
Our objectives are, using our unique experimental model of ADHF, to determine:
  1. the cellular and molecular mechanisms of cardiac proteomic-metabolic modulation by O-GlucNASe inhibition with the pharmacological compound Thiamet G
  2. whether there is a therapeutic window for O-GlucNASe inhibition during onset of ADHF
  3. whether the beneficial cardiac effects are shared within the new pharmacological class of O-GlucNASe inhibitors
  4. identify circulating biomarkers to monitor effects of O-GlcNAcase inhibition using clinical samples from ADHF patient cohorts
Specifically, by using pharmacological O-GlucNASe inhibitors currently under clinical phase 2/3 development in Alzheimer disease, the GANDHI project will pave the way for a rapid transfer of O-GlucNASe inhibitors as an innovative treatment approach for ADHF.